Abstract
BackgroundDiagnosis of asthma and chronic obstructive pulmonary disease (COPD) in the community is variable, often without spirometry. Some studies report that adults with both diagnostic labels (asthma+COPD) have worse health outcomes than those with asthma or COPD only, but data for Australian adults are limited. We investigated the relationship between clinical characteristics and self-reported diagnoses of asthma, COPD and both.MethodWe used data from the BOLD Australia study, which included randomly selected adults aged ≥40 years from six study sites. The BOLD questionnaires and spirometry test were used in all sites. Participants were grouped by self-reported diagnosis. Demographic and clinical characteristics and lung function were compared between groups.ResultsOf the study sample (n=3522), 336 reported asthma only, 172 reported COPD only, 77 reported asthma+COPD and 2937 reported neither. Fewer than half of participants with a COPD diagnosis (with or without asthma) had airflow limitation. Participants with asthma+COPD had more respiratory symptoms and greater airflow limitation than those with either diagnosis alone. Having asthma+COPD was independently associated with a higher probability of having clinically important breathlessness (modified Medical Research Council score ≥2) than asthma only (adjusted OR 3.44, 95% CI 1.86–6.33) or COPD only (adjusted OR 3.28, 95% CI 1.69–6.39). Airflow limitation (Global Initiative for Chronic Obstructive Lung Disease 2 or higher, using post-bronchodilator forced expiratory volume in 1 s/forced vital capacity ratio <0.7) was similar between asthma only and COPD only, but twice as prevalent in asthma+COPD (adjusted OR 2.18 and 2.58, respectively).ConclusionsAdults with diagnoses of asthma+COPD have a higher symptom and disease burden than those with diagnoses of asthma only or COPD only. These patients should receive regular comprehensive reviews because of the substantially increased burden of having both diagnoses.
Funder
Boehringer Ingelheim Australia
GlaxoSmithKline Australia
National Health and Medical Research Council
AstraZeneca Australia
Pfizer Australia
Air Liquide Australia
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference39 articles.
1. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
2. Australian Institute of Health Welfare . Disease Expenditure in Australia 2018–19. www.aihw.gov.au/reports/health-welfare-expenditure/disease-expenditure-australia Date last updated: 25 August 2021. Date last accessed: 3 June 2022.
3. Global Initiative for Asthma (GINA) . GINA Report, Global Strategy for Asthma Management and Prevention. 2022. Available from: https://ginasthma.org/gina-reports/ Date last updated: 10 May 2022. Date last accessed: 10 May 2022.
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global Strategy for Prevention, Diagnosis and Management of COPD. 2023. Available from: https://goldcopd.org/2023-gold-report-2/ Date last updated: 5 December 2022. Date last accessed: 5 December 2022.
5. The overlap syndrome of asthma and COPD: what are its features and how important is it?